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Abstract
Background: Several lines of evidence strongly suggest that agouti-related peptide (AGRP) plays
a key role in the regulation of metabolic function but ablation of the AGRP gene has no apparent
effect on metabolic function. Since specific pharmacological antagonists of AGRP do not presently
exist, we assessed if reduction of hypothalamic AGRP mRNA by RNA interference (RNAI) would
influence metabolic function, an outcome suggesting that pharmacological antagonists might
constitute useful reagents to treat obesity.
Results: The RNAI protocol specifically reduced hypothalamic expression of AGRP mRNA by 50%
and resulted in reduction of AGRP peptide immunoreactivity. Physiologically, the reduction in
AGRP levels was associated with increased metabolic rate and reduced body weight without
changes in food intake.
Conclusion: AGRP can function to increase body weight and reduce metabolic rate without
influencing food intake. The present study demonstrates that RNAI protocols can be used to assess
physiological function of neuronal genes in vivo.
Background
Agouti-related peptide (AGRP) gene expression is elevated
by fasting and in obesity due to leptin insufficiency [1,2],
while reversal of obese phenotypes by adrenalectomy re-
verses the elevation of AGRP mRNA [3]. Injections of syn-
thetic analogs of AGRP, and of AGRP itself, also stimulate
food intake and body weight [4,5]. Together with the ob-
servation that transgenic over-expression of the AGRP
gene leads to hyperphagia and obesity [1], these data sug-
gest that antagonism of AGRP may reduce food intake and
body weight, thus potentially serving as a therapy for
obesity.
RNAI produces sequence-specific reduction of gene ex-
pression in various mammalian in vitro systems [6] and
most recently, RNAI was shown to suppress the expression
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and activity of a luciferase transgene in adult mice [7], sug-
gesting that RNAI may become a valuable molecular and
possibly clinical tool for use in vivo. A major advantage of
RNAI over a similar protocol, using antisense oligonucle-
otides, is that the use of antisense oligonucleotides to as-
sess chronic effects requires constant or repetitive
infusion, is expensive and generally impractical for more
than a few days. In contrast, RNAI can be used to study
long-term phenotypes (including body weight and mem-
ory functions) due to the development of a DNA plasmid-
based system to deliver short double-stranded RNA se-
quences in vivo[8]. While RNAI has been extensively used
to assess physiological functions of specific genes in C. el-
egans and Drosophila [9,10] and a single recent paper has
reported that RNAI can reduce gene expression in vivo (in
liver) [7], the applicability of RNAI to assess physiological
or neuronal function in mammals has not yet been dem-
onstrated.
Here we show, using both small interfering RNA (siRNA)
particles and the plasmid based RNAI delivery system,
pSUPER-RNAI, that decreasing endogenous hypothalam-
ic AGRP levels in the central nervous system leads to sig-
nificant physiological responses including an increase in
metabolic rate and a decrease in body weight.
Results and Discussion
Effects of small interfering RNA particles against AGRP
SiRNA particles against both AGRP and GFP were de-
signed based on reports by Elabashir et al. [6] (Fig. 1a). In-
jection of these siRNA particles into the arcuate nucleus of
the hypothalamus reduced AGRP mRNA about 50% 24
hours after injection, compared to the control group in-
jected with siRNA particles targeted to GFP (Fig. 1b and
1c). The 50% decrease in expression level is similar to pre-
viously reported effects of RNAI to reduce gene expression
from 40–80% both in vitro[6] and in vivo[7] in mammali-
an systems. Since the construct targeted to AGRP reduced
AGRP expression relative to the construct targeted to GFP,
this result indicates specific down-regulation by the AGRP
RNAI construct.
The decrease in AGRP mRNA was associated with a strik-
ing increase in metabolic rate. Both heat production (Fig.
2a; p < 0.0001) and oxygen consumption, VO2 (Fig. 2b; p
< 0.0003) were elevated one day after infusion of the
AGRPi construct. Metabolic rate continued to be elevated
during day 2 (heat production p < 0.0001; VO2 p <
0.0494). However, by 3 days after infusion, metabolic rate
returned to control levels. This result indicates that AGRP
normally acts to reduce metabolic rate, consistent with
conclusions from indirect evidence based on pair-fed ani-
mals treated with AGRP [11].
The decrease in AGRP mRNA and increase in metabolic
rate was associated with a trend to decrease body weight,
but this effect was not significant over the 48 hours after
injection (body weight loss of -1.72  0.66 g for the GFPi
control mice compared to a loss of -2.85  0.52 g for the
AGRPi mice). Surprisingly, decrease in AGRP mRNA did
not significantly influence food intake compared to con-
trols (mean intake of 5.0  0.7 g/day for the GFPi control
mice compared to 5.3  0.6 g/day for the AGRPi mice).
Since both the AGRPi and the control GFPi mice were still
recovering from the effects of the surgery and anesthesia at
48 hours, it is not surprising that the effects on body
weight were not statistical at this time. Nevertheless the
lack of an effect on food intake was unexpected since treat-
ment with synthetic AGRP peptides has profound effects
on food intake [4,5].
Figure 1
Small interfering RNA (siRNA) particles decreases AGRP
mRNA. (a) Synthetic siRNA particle designed against AGRP
mRNA. (b) Representative bands from the Northern blot 24
hours after injection shows decreased levels of AGRP mRNA
in the group injected with AGRP-siRNA particle compared
to the control GFPi-siRNA injections. (c) Quantification of
the Northern blot results yields a statistically significant
decrease in expression of 50% with the AGRP-siRNA parti-
cle. Data are expressed as a mean percentage  SEM of GFP-
siRNA levels (n = 16; p < 0.05).
Synthetic siRNA against AGRP:
5'-CUGAGUUGUGUUCUGCUGUUGTT–3’
3’-TTGACUCAACACAAGACGACAAC–5’
a.
b.
c.
Representative Northern blot bands
GFPi AGRPi
(cont’l) (exp’t)
GFPi AGRPi
(cont’l) (exp’t)
0
120
A
G
R
P
m
R
N
A
(
%
G
F
P
i
)
*BMC Neuroscience 2002, 3 http://www.biomedcentral.com/1471-2202/3/18
Page 3 of 6
(page number not for citation purposes)
Effects of the plasmid based RNAI protocol against AGRP
Since it was anticipated that double-stranded RNAI parti-
cles, like antisense oligonucleotides, would produce only
very transient reduction in mRNA levels, and indeed the
effect on physiological function was only transient, we
next assessed effects of AGRP RNAI using a plasmid-based
system, pSUPER [8] (Fig. 3a), which leads to the transcrip-
tion of a short double stranded RNA product with a hair-
pin loop in vivo. Using luciferase as a reporter we observed
that liposome-mediated transfection of plasmids into
brain parenchyma allows significant gene expression for
more than one week after infusion [12]. Transfection of
neurons in the arcuate nucleus of the hypothalamus led to
a decrease in AGRP peptide immunoreactivity, whereas
transfection with the control plasmid targeted to GFP had
no effect on AGRP immunoreactivity (Fig. 3b,3c). The ef-
fect of RNAI to reduce AGRP gene expression was there-
fore also associated with decreased expression of the
AGRP peptide.
The persistent effect of the pSUPER vector to reduce the
levels of AGRP peptide was associated with a significant
reduction in body weight that persisted over six days (Fig.
4a; p < 0.0001). While the control group recovered body
weight initially lost due to surgery, the pSUPER-AGRPi
group did not regain the body weight lost. In contrast, as
with the double-stranded RNAI construct, infusion of the
plasmid-based AGRP RNAI construct did not significantly
reduce food intake compared to infusion of the plasmid-
based GFP RNAI construct (Fig. 4b; p = 1.6992). Food in-
take was minimal immediately following surgery, howev-
er, both groups of mice recovered to consume four to five
grams of food per day. The loss of body weight, without
changes in food intake is consistent with increases in met-
abolic rate observed with the siRNA protocol. This result
supports the hypothesis that tonic hypothalamic AGRP re-
duces metabolic rate independent of food intake, and in-
deed that metabolic rate may be even more dependent on
AGRP tone than is food intake.
Conclusions
In summary, the present report represents the first demon-
stration that RNA interference can be used to reduce ex-
pression of an endogenous gene in adult mammals. This
protocol has allowed us to assess the physiological func-
tion of an endogenous neuronal gene. This study also di-
rectly indicates that hypothalamic AGRP regulates
metabolic rate. The observation that reduction of AGRP
mRNA would produce more profound effects on metabol-
ic rate than on food intake was surprising since infusion
of AGRP peptide produces profound effects on food in-
take [4,5]. However, since neither AGRP mRNA nor pep-
tide was completely ablated, it seems likely that effects on
food intake would become more apparent with a more
dramatic manipulation. Although ablation of the AGRP
gene was reported to have no effect on metabolic pheno-
type [13], our results suggest that complete ablation of the
gene may have produced metabolic compensation. Thus
reducing (but not ablating) AGRP expression in adult
mice may have identified a metabolic role for AGRP not
apparent from complete ablation of the gene, suggesting
that agents antagonizing the effect of AGRP may be useful
to treat obesity without producing unacceptable loss of
appetite. Consistent with previous findings in mammali-
an systems [6–8] and unlike other systems such as C. ele-
gans and Drosophila [9,10], RNAI reduced but did not
eliminate expression of AGRP. However, improvements
in delivery systems, especially in conjunction with viral-
based gene transfer protocols [14], could result in greater
and even longer-term reduction of target gene expression
Figure 2
Decreasing AGRP levels with siRNA increases metabolic
rate.  (a) Heat production for AGRP-siRNA injected mice
was found to be significantly and dramatically elevated one
day following surgery compared to the control injected GFP-
siRNA mice (n = 16; p < 0.0001). (b) Oxygen consumption,
VO2, was also significantly elevated one day after surgery for
mice injected with the AGRP-siRNA particles (n = 16; p <
0.0003).
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suggesting that RNAI will prove to be a useful tool to as-
sess physiological functions of mammalian genes in vivo,
especially those expressed in the brain, as RNAI has been
so useful in functional mapping of genes in non-mamma-
lian systems.
Methods
Animal and RNAI protocols
The appropriate Institutional Animal Review Board had
approved all studies. To study the effects of RNAI, C57Bl/
6J mice retired breeders were obtained from The Jackson
Laboratory (Bar Harbor, ME). Mice were individually
housed with free access to food and water under 12:12 h
light-dark cycle (lights on at 07:00 h). Stereotaxic surgery
was performed under anesthesia (2.5% 2-2-2-tribro-
moethanol, 0.015–0.017 ml/g body weight, i.p.). The
RNAI constructs were injected bilaterally using a 1 ul
Figure 3
pSUPER-AGRPi construct decreases AGRP immunoreactiv-
ity.  (a) Overall design of the pSUPER-RNAI plasmid con-
struct targeted against AGRP and the predicted transcript
with the hairpin loop. (b and c) Immunocytochemistry of
fasted mice transfected with the (b) control pSUPER-GFPi
vector compared to (c) mice transfected with the pSUPER-
AGRPi vector shows decreased AGRP immunoreactivity
with the RNAI plasmid construct targeted to AGRP.
Figure 4
Decreasing AGRP levels by pSUPER-AGRPi construct
decreases body weight (a) Mice transfected with the pSU-
PER-AGRPi construct shows persistent loss of body weight
after transfection while the mice transfected with the control
vector recover body weight over a course of six days (n =
14; p < 0.0001). (b) pSUPER-RNAI targeted to AGRP has no
effect on mean daily food intake (n = 14; p = 1.6992).
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Hamilton syringe placed on a stereotaxic frame into the
following coordinates from bregma: anterior-posterior -
0.12; lateral  0.02; vertical -0.6. Double-stranded siRNA
particles to reduce expression of AGRP were designed
based on Elbashir et al. [6] (Fig. 1a). The siRNA oligonu-
cleotides were designed from the beginning of exon 1 of
both AGRP and GFP genes and ordered gel-purified and
annealed from Oligos Etc. (Wilsonville, OR). SiRNA par-
ticles were re-suspended in Rnase-free water to a concen-
tration of 1 mM and 0.5 ul was injected over 2 minutes by
stereotaxic surgery bilaterally. The pSUPER-RNAI plasmid
constructs were re-suspended in lipofectin (Invitrogen
Corp. Carlsbad, CA) to a concentration of 1 ug/ul, and 1
ul of the mixture was injected bilaterally over five minutes
using the same coordinates as for the siRNA particles.
Body weight and food intake was monitored daily.
Metabolic rate was monitored continuously by indirect-
calorimetry for three days following surgery. Air from each
cage was sampled every five minutes, and oxygen and car-
bon dioxide concentrations from each sample were meas-
ured independently. From the change in oxygen, VO2 or
oxygen consumption can be calculated after normalizing
to body weight. Heat production can then be calculated
using the following formula: Heat (cal/hour) =
((4.33+0.67  (VCO2/VO2))  VO2  (Body weight) 
60). Therefore, the parameter VO2 is normalized to body
weight, whereas heat production is not normalized to
body weight.
For Northern blot analysis, all mice were sacrificed toward
the end of the light period (between 17:00 and 19:00 h)
by decapitation after a brief exposure to carbon dioxide.
Brains were quickly removed and the hypothalamus was
dissected out, frozen on dry ice and stored at -70C until
use. For immunocytochemistry, mice were perfused with
cold PBS followed by 4% paraformaldehyde. Brains were
removed, post-fixed in paraformaldehyde then preserved
in 30% sucrose solution for 48 hours.
Northern blot analysis
Total RNA was extracted from tissue using TRIzol (GIBCO
BRL, Gaitherburg, MD). Concentration of the samples
were measured by UV spectrophotometer and normalized
to 1 ug/ul. Uniform concentration and integrity of the
samples were verified by agarose gel electrophoresis prior
to Northern blot analysis. Six micrograms of total RNA
from hypothalamus was subjected to Northern blot anal-
ysis, as described previously, to measure AGRP mRNA
[15,16,2,3]. Briefly, RNA was denatured by incubating
with glyoxal and dimethyl sulfoxide for 1 hour at 50C
and separated on a 1.5% agarose 10 mM NaPO4 (pH =
7.0) gel for 1 hour at 100 V. The RNA was then transferred
to an Immobilon S (Millipore) membrane by capillary
elution overnight in 20  standard saline citrate (SSC)
buffer. Membranes were briefly washed in 6  SSC, baked
at 80C and cross-linked by UV light. The membranes
were prehybridized in Ultrahyb buffer (Ambion) at 68C
for 2 hours and hydribized overnight with 3.5  106 DPM/
ml of probe at 42C. The blots were probed with single-
stranded internally labeled DNA probe as described previ-
ously [17]. The membranes were washed twice in 1  SSC/
0.1% SDS solution for 15 minutes at room temperature,
followed by 0.1  SSC/0.1% SDS solution for 15 minutes
at room temperature twice and then for 3 hours at 42C.
The membranes were then exposed to phosphoimager
screen overnight. The total integrated densities of hybrid-
ization signals were determined by phosphoimager
(STORM 860, Molecular Dynamics, Sunnyvale, CA). To
monitor RNA loading, membranes were re-probed and
hybridized with a 32P-labeled probe encoding 18S ribos-
omal RNA.
Immunocytochemistry
Cryopreserved brains were cut to a thickness of 30 um in
a cryostat at -20C and stored in PBS-B buffer (10 mM
PO4 in 0.9% NaCl) containing 0.1% sodium azide at 4C.
Immunocytochemistry was performed with a rabbit poly-
clonal primary antibody to AGRP peptide diluted 1 to
10,000 (Phoenix Pharmaceuticals, Belmont, CA) fol-
lowed by Vectastain ABC kit (Vector Laboratories, Burlin-
game, CA). The immunoreactivity was visualized with the
Vector VIP kit (Vector Laboratories, Burlingame, CA). Sec-
tions were mounted on microscopic slides, air-dried and
cover slipped with VectaMount (Vector Laboratories, Bur-
lingame, CA).
Statistical Analysis
Statistical analysis for the Northern blot was performed by
student's t-test, using the JMP statistical package imple-
mented on the Macintosh operating system. A p-value of
less than 0.05 was considered significant. For the analysis
of the metabolic cage data, a two-way ANOVA (time 
RNAI construct) was performed using the JMP statistical
package. For analysis of food intake and body weight, a
two-way ANOVA (time  RNAI construct) followed,
where indicated, by student's t-test (p < 0.05 was consid-
ered significant) was performed to compare each inde-
pendent time point.
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